Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer
Key Points
-
The INAVO120 trial is the first to demonstrate overall survival (OS) improvement with a PI3K inhibitor.
-
Leading oncologists discussed the use of first-line inavolisib plus palbociclib-fulvestrant versus placebo plus palbociclib-fulvestrant in hormone receptor (HR)–positive, HER2-negative locally advanced or metastatic breast cancer.
-
Breast cancer experts provided insight into novel selective estrogen receptor degraders, treatment for ESR1-mutant tumors, and patient-reported outcomes.
Patients with breast cancer have more treatment options than ever before as cutting-edge therapies begin to reach clinical practice.
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Komal Jhaveri, MD, FACP, of Memorial Sloan Kettering Cancer Center, highlighted some of the meeting’s biggest takeaways for the treatment of HR-positive, HER2-negative metastatic breast cancer.
The INAVO120 clinical trial is the first to show improved OS with a PI3K inhibitor—inavolisib—in the first-line setting. Researchers investigated inavolisib plus palbociclib-fulvestrant in patients with HR-positive, HER2-negative locally advanced or metastatic disease compared with patients who were given placebo plus palbociclib-fulvestrant. Median OS data, which were presented at ASCO, favored the triplet arm versus placebo (34 months vs 27 months, respectively). The regimen also significantly improved progression-free survival.
In addition to covering INAVO120 data, Dr. Jhaveri discussed novel selective estrogen receptor degraders, treatment for ESR1-mutant tumors, and patient-reported outcomes. She shared her excitement for potential combination therapies that may include new cell cycle, PI3K, and KAT 6 inhibitors with Matthew Kurian, MD, of St. Elizabeth Healthcare.